Fabino Enterprises Limited
BSE: FABINO · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Fabino Enterprises Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Fabino Life Sciences Limited is an Indian pharmaceutical company focused on the manufacturing, marketing, and distribution of allopathic, herbal, and veterinary medicines. The company also offers a range of consumer healthcare and wellness products, including personal care items like soaps and sanitizers.
Business Model
The company operates on a contract manufacturing model, outsourcing production while concentrating its internal resources on brand development and market penetration. It serves both ethical and over-the-counter segments within the domestic Indian pharmaceutical market.
Growth Outlook
Growth is driven by expanding market penetration for its diverse therapeutic portfolio and maintaining a focus on providing affordable healthcare solutions. The company aims to leverage its presence in both pharmaceutical and consumer wellness segments to capture broader market share.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical regulations and quality standards, where any failure to comply could lead to product recalls or operational disruptions.
- Contract Manufacturing Dependency. Reliance on third-party manufacturers exposes the company to risks regarding supply chain stability, production quality, and cost fluctuations.
- Market Competition. The Indian pharmaceutical and consumer healthcare sectors are highly competitive, potentially impacting profit margins and market share.
- Pricing Pressures. Government-mandated price controls on essential medicines may limit the company's ability to maintain margins on its pharmaceutical product range.
Start your research today
Unlock AI insights, financials, peers and live data on Fabino Enterprises Limited and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Fabino Enterprises LimitedFABINO | — | — | — | — | -9.9% | — | — | — |
Sun Pharmaceutical Industries Ltd.SUNPHARMA | ₹4.61L Cr | 38.10 | 22.66 | 11.4% | 33.5% | 15.6% | 20.5% | +20.4% |
Divi's Laboratories Ltd.DIVISLAB | ₹2.45L Cr | 83.83 | 55.47 | 16.3% | 39.3% | 18.4% | 23.1% | +50.7% |
Torrent Pharmaceuticals Ltd.TORNTPHARM | ₹1.92L Cr | 80.67 | 40.17 | 32.9% | 32.6% | 27.0% | 15.1% | +41.9% |
Zydus Lifesciences Ltd.ZYDUSLIFE | ₹1.20L Cr | 26.54 | 14.90 | 21.1% | 30.7% | 18.0% | 20.1% | +21.4% |
Cipla Ltd.CIPLA | ₹1.15L Cr | 34.10 | 18.63 | 1.8% | 21.6% | 10.2% | 13.6% | -10.4% |
As of Mar 2026
Financials
Fabino Enterprises Limited
BSE: FABINO · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Fabino Enterprises Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Fabino Life Sciences Limited is an Indian pharmaceutical company focused on the manufacturing, marketing, and distribution of allopathic, herbal, and veterinary medicines. The company also offers a range of consumer healthcare and wellness products, including personal care items like soaps and sanitizers.
Business Model
The company operates on a contract manufacturing model, outsourcing production while concentrating its internal resources on brand development and market penetration. It serves both ethical and over-the-counter segments within the domestic Indian pharmaceutical market.
Growth Outlook
Growth is driven by expanding market penetration for its diverse therapeutic portfolio and maintaining a focus on providing affordable healthcare solutions. The company aims to leverage its presence in both pharmaceutical and consumer wellness segments to capture broader market share.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical regulations and quality standards, where any failure to comply could lead to product recalls or operational disruptions.
- Contract Manufacturing Dependency. Reliance on third-party manufacturers exposes the company to risks regarding supply chain stability, production quality, and cost fluctuations.
- Market Competition. The Indian pharmaceutical and consumer healthcare sectors are highly competitive, potentially impacting profit margins and market share.
- Pricing Pressures. Government-mandated price controls on essential medicines may limit the company's ability to maintain margins on its pharmaceutical product range.
Start your research today
Unlock AI insights, financials, peers and live data on Fabino Enterprises Limited and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026